Team
The LumaBridge team is a group of passionate leaders and experienced clinical development professionals who embody our mission to bring new therapies to patients while building high-performing teams. Their commitment to excellence and to providing quality service embodies the foundation on which LumaBridge is built and drives our pathway to successful outcomes for our customers and the patients we serve.
Todd M. Lehman, MS
Chief Executive Officer
Todd Lehman joined LumaBridge in 2023 with over 20 years of experience in the client services space across both commercial and clinical operations. Prior to joining LumaBridge, Mr. Lehman held various leadership roles in operations and portfolio management with a focus on the biotech customer during his tenure at PPD, part of Thermo Fisher Scientific. He got his start in the industry with Rx Development Resources, a start-up niche CRO that transformed into a small biotech, Sirion Therapeutics, and successfully in-licensed 5 ophthalmology assets while receiving 2 marketing approvals.
Mr. Lehman has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor degree in chemical engineering and a master in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Mr. Lehman spent about 10 years in retail and b2b commodity sales.
Chief Executive Officer
Todd Lehman joined LumaBridge in 2023 with over 20 years of experience in the client services space across both commercial and clinical operations. Prior to joining LumaBridge, Mr. Lehman held various leadership roles in operations and portfolio management with a focus on the biotech customer during his tenure at PPD, part of Thermo Fisher Scientific. He got his start in the industry with Rx Development Resources, a start-up niche CRO that transformed into a small biotech, Sirion Therapeutics, and successfully in-licensed 5 ophthalmology assets while receiving 2 marketing approvals.
Mr. Lehman has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor degree in chemical engineering and a master in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Mr. Lehman spent about 10 years in retail and b2b commodity sales.
Amanda Ferrier, RN, PMP
Chief Operating Officer
Amanda Ferrier is an experienced clinical operations executive who specializes in organizational development and strategic planning through the harmonization of people, processes, and scientific discovery. With over 20 years of global biopharmaceutical experience, she is responsible for overseeing the cohesiveness and efficiency of the LumaBridge operations team and ensuring strategic execution of the clinical drug development lifecycle while addressing increasingly complex client needs and evolving drug development processes.
Before joining LumaBridge, Ms. Ferrier served in various leadership positions at both CRO and sponsor organizations, where she was instrumental in streamlining operational delivery and spearheading specialized processes such as cell and gene therapy operational strategies and logistics. Her experience spans several therapeutic areas, with a focus on hematology/oncology and rare diseases as well as areas of increasing innovation, such as biomarkers, cell and gene therapies, and vaccines. She also supported CRO global business expansion and Asia-Pacific team development while in these roles.
Ms. Ferrier began her research career at ILEX Oncology, Inc. (acquired by Genzyme 2004), in San Antonio, Texas, where she was fortunate enough to contribute to the approval of clofarabine (CLOLAR®), the first of over 25 NDAs throughout her career. She is a Registered Nurse, a Certified Project Management Professional (PMP), and a Lean Six Sigma Yellow Belt. Ms. Ferrier holds a bachelor of science from Texas A&M University and another bachelor of science from The University of Texas Health Science Center, and she began MBA coursework from Suffolk University in Boston.
Chief Operating Officer
Amanda Ferrier is an experienced clinical operations executive who specializes in organizational development and strategic planning through the harmonization of people, processes, and scientific discovery. With over 20 years of global biopharmaceutical experience, she is responsible for overseeing the cohesiveness and efficiency of the LumaBridge operations team and ensuring strategic execution of the clinical drug development lifecycle while addressing increasingly complex client needs and evolving drug development processes.
Before joining LumaBridge, Ms. Ferrier served in various leadership positions at both CRO and sponsor organizations, where she was instrumental in streamlining operational delivery and spearheading specialized processes such as cell and gene therapy operational strategies and logistics. Her experience spans several therapeutic areas, with a focus on hematology/oncology and rare diseases as well as areas of increasing innovation, such as biomarkers, cell and gene therapies, and vaccines. She also supported CRO global business expansion and Asia-Pacific team development while in these roles.
Ms. Ferrier began her research career at ILEX Oncology, Inc. (acquired by Genzyme 2004), in San Antonio, Texas, where she was fortunate enough to contribute to the approval of clofarabine (CLOLAR®), the first of over 25 NDAs throughout her career. She is a Registered Nurse, a Certified Project Management Professional (PMP), and a Lean Six Sigma Yellow Belt. Ms. Ferrier holds a bachelor of science from Texas A&M University and another bachelor of science from The University of Texas Health Science Center, and she began MBA coursework from Suffolk University in Boston.
Steven White
Chief Business Officer
Steven White is the CBO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work. He believes in the mission—and the people—of LumaBridge.
During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.
Chief Business Officer
Steven White is the CBO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work. He believes in the mission—and the people—of LumaBridge.
During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.
Jane Hart, MBA, BAppSci Hons
Vice President, Clinical Operations
Jane Hart joined LumaBridge in 2022 and is a highly experienced executive in clinical operations and clinical affairs, with more than 25 years of experience in the clinical research industry shepherding products from concept through to global approvals. She holds a bachelor of applied science honors from Charles Sturt University in Australia and an executive master of business administration (EMBA) from the University of Texas at San Antonio.
Vice President, Clinical Operations
Jane Hart joined LumaBridge in 2022 and is a highly experienced executive in clinical operations and clinical affairs, with more than 25 years of experience in the clinical research industry shepherding products from concept through to global approvals. She holds a bachelor of applied science honors from Charles Sturt University in Australia and an executive master of business administration (EMBA) from the University of Texas at San Antonio.
Dalal Murgai
Vice President, Regulatory Affairs and Quality Assurance
Dalal Murgai joined LumaBridge in 2023 as the new head of regulatory affairs and quality assurance and is a subject matter expert responsible for performing clinical quality assurance and regulatory activities, including medical writing, in support of and in accordance with FDA regulations and ICH guidelines and standard operating procedures.
Ms. Murgai’s career has centered on drug development, with 35+ years of bench research and drug and biologics product development experience in the biopharmaceutical/medical research industry and 30+ years’ experience in GLP, GCP, and GMP quality assurance and regulatory affairs. Areas of expertise include GXP compliance and training, medical/technical writing, operational issue resolution, managing interactions with regulatory agencies, and authoring/review and evaluation of standard operating procedures, technical, and regulatory submissions in paper and in eCTD format (ie, INDs, NDA/BLAs, CTAs, MAAs, and routine updates and amendments). She has led the development and implementation of quality management systems (QMS) for start-ups as well as several larger companies to support the development of small molecule drugs, large molecule biologics, and cellular therapies.
Prior to LumaBridge, Ms. Murgai co-founded and was the chief operating officer of GXP Quality Systems, LLC (GXPQS), a consulting firm that advises companies in the development of QMS, and prior to that founded Regulatory Outsource Consulting, Inc., another firm that consulted on quality and regulatory matters relating to the clinical phases of manufacturing and testing of drugs/biologics in animal, laboratory, and clinical studies.
Vice President, Regulatory Affairs and Quality Assurance
Dalal Murgai joined LumaBridge in 2023 as the new head of regulatory affairs and quality assurance and is a subject matter expert responsible for performing clinical quality assurance and regulatory activities, including medical writing, in support of and in accordance with FDA regulations and ICH guidelines and standard operating procedures.
Ms. Murgai’s career has centered on drug development, with 35+ years of bench research and drug and biologics product development experience in the biopharmaceutical/medical research industry and 30+ years’ experience in GLP, GCP, and GMP quality assurance and regulatory affairs. Areas of expertise include GXP compliance and training, medical/technical writing, operational issue resolution, managing interactions with regulatory agencies, and authoring/review and evaluation of standard operating procedures, technical, and regulatory submissions in paper and in eCTD format (ie, INDs, NDA/BLAs, CTAs, MAAs, and routine updates and amendments). She has led the development and implementation of quality management systems (QMS) for start-ups as well as several larger companies to support the development of small molecule drugs, large molecule biologics, and cellular therapies.
Prior to LumaBridge, Ms. Murgai co-founded and was the chief operating officer of GXP Quality Systems, LLC (GXPQS), a consulting firm that advises companies in the development of QMS, and prior to that founded Regulatory Outsource Consulting, Inc., another firm that consulted on quality and regulatory matters relating to the clinical phases of manufacturing and testing of drugs/biologics in animal, laboratory, and clinical studies.
Lee Walke, MS
Vice President, Biometrics
Lee Walke brings a rich history of innovation in statistical programming, data management, and clinical research technology to LumaBridge. Working for PRA from 1990 to 2007, he guided biometrics and submissions activities for 6 New Drug Applications, and then he applied his expertise in biometrics to support postapproval (late-phase) research.
Late-phase research brought the site’s growing research workload into clear focus, and he deployed technology to pragmatically ease this burden. Leading the Biometrics team for MAPI, he worked to simplify electronic case report forms (eCRFs), streamline data management, offer friction-free grant payments, and provide one-click access to patient profiles. This focus on improving the site’s experience with research evolved into expertise in risk-based monitoring and enriching study databases with data sourced directly from patients and electronic health records (EHRs). Mr. Walke’s experience with EHRs for research includes not only enhanced study databases but also methods to locate patient candidates for clinical trials. His aim is to allow sites to focus more on patient care and research and less on data entry and administration.
Mr. Walke holds a BA and MS in Management Information Systems from the University of Virginia.
Vice President, Biometrics
Lee Walke brings a rich history of innovation in statistical programming, data management, and clinical research technology to LumaBridge. Working for PRA from 1990 to 2007, he guided biometrics and submissions activities for 6 New Drug Applications, and then he applied his expertise in biometrics to support postapproval (late-phase) research.
Late-phase research brought the site’s growing research workload into clear focus, and he deployed technology to pragmatically ease this burden. Leading the Biometrics team for MAPI, he worked to simplify electronic case report forms (eCRFs), streamline data management, offer friction-free grant payments, and provide one-click access to patient profiles. This focus on improving the site’s experience with research evolved into expertise in risk-based monitoring and enriching study databases with data sourced directly from patients and electronic health records (EHRs). Mr. Walke’s experience with EHRs for research includes not only enhanced study databases but also methods to locate patient candidates for clinical trials. His aim is to allow sites to focus more on patient care and research and less on data entry and administration.
Mr. Walke holds a BA and MS in Management Information Systems from the University of Virginia.
Dennis Ferrante
Vice President, Information Technology
Dennis Ferrante joined LumaBridge in 2022, bringing 20 years of experience in IT and analytics. Prior to joining LumaBridge, Dennis held various leadership roles in IT with a focus on clinical applications, securities, and analytics at Brown University’s Department of Emergency Medicine. He got his start in IT at DELL/EMC, where he helped grow a global technical support department and foster new employees into the workplace.
Mr. Ferrante has experience across several IT disciplines, including clinical applications, IT policy and procedures, and hardware. Along with IT, Dennis has excelled in data analytics in the clinical space, where he helped organizations create a backend data architecture and feed it into frontend tools like Tableau and PowerBi to enable accurate business–level decisions and forecasting.
Vice President, Information Technology
Dennis Ferrante joined LumaBridge in 2022, bringing 20 years of experience in IT and analytics. Prior to joining LumaBridge, Dennis held various leadership roles in IT with a focus on clinical applications, securities, and analytics at Brown University’s Department of Emergency Medicine. He got his start in IT at DELL/EMC, where he helped grow a global technical support department and foster new employees into the workplace.
Mr. Ferrante has experience across several IT disciplines, including clinical applications, IT policy and procedures, and hardware. Along with IT, Dennis has excelled in data analytics in the clinical space, where he helped organizations create a backend data architecture and feed it into frontend tools like Tableau and PowerBi to enable accurate business–level decisions and forecasting.
COL (ret) George E. Peoples, MD, FACS
Founder and Executive Chairman
COL (ret) George E. Peoples, MD, FACS, is the founder and executive chairman of LumaBridge (formerly Cancer Insight [CI]) and Trauma Insight (TI). He served 30 years of active duty as a surgeon and research scientist in the military and was founder and director of the Cancer Vaccine Development Program (CVDP). The CVDP has over 20 years of experience in the discovery, development, and clinical testing of cancer vaccines, including 5 that have been licensed for commercial development. In 2014, Dr. Peoples retired from the military and founded CI and TI.
Dr. Peoples serves as a professor of surgery at Uniformed Services University of the Health Sciences and professor (adjunct) of surgical oncology at MD Anderson Cancer Center (MDACC). He is the former chair of the Cancer Care Program at the San Antonio Military Medical Center and the past military director of the United States Military Cancer Institute. He is a graduate of the United States Military Academy at West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MDACC. He has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts, and book chapters.
Founder and Executive Chairman
COL (ret) George E. Peoples, MD, FACS, is the founder and executive chairman of LumaBridge (formerly Cancer Insight [CI]) and Trauma Insight (TI). He served 30 years of active duty as a surgeon and research scientist in the military and was founder and director of the Cancer Vaccine Development Program (CVDP). The CVDP has over 20 years of experience in the discovery, development, and clinical testing of cancer vaccines, including 5 that have been licensed for commercial development. In 2014, Dr. Peoples retired from the military and founded CI and TI.
Dr. Peoples serves as a professor of surgery at Uniformed Services University of the Health Sciences and professor (adjunct) of surgical oncology at MD Anderson Cancer Center (MDACC). He is the former chair of the Cancer Care Program at the San Antonio Military Medical Center and the past military director of the United States Military Cancer Institute. He is a graduate of the United States Military Academy at West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MDACC. He has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts, and book chapters.
Mark deLaar
Summit Partners | Board Member
Mark deLaar joined Summit Partners in 2003 and focuses primarily on the healthcare services & technology and life sciences sectors. His current board directorships include Club Champion, eClinical Solutions, EHE, LumaBridge, and ModMed.
Mr. deLaar’s previous board and investment experience includes Advance Health (acquired by New Mountain Capital), Anesthetix (acquired by TeamHealth), Autobase (acquired by Dominion Enterprises), COMS Interactive (acquired by PointClickCare), Fermentas International (acquired by Thermo Fisher Scientific), Immco Diagnostics (acquired by Trinity Biotech), LakePharma (acquired by Curia), MDVIP (acquired by Goldman Sachs and Charlesbank Capital), My Dentist Holdings (acquired by Heartland Dental Care), OB Hospitalist Group (acquired by Ares Management), Surgical Affiliates Management Group (SAMGI – acquired by Varsity Healthcare Partners), and Wellcentive (acquired by Philips).
Prior to Summit, Mr. deLaar worked for DB Alex Brown, Banc of America Securities and Public Financial Management, and served in the United States Army. He holds a BS from the United States Military Academy and an MBA from the MIT Sloan School of Management.
Summit Partners | Board Member
Mark deLaar joined Summit Partners in 2003 and focuses primarily on the healthcare services & technology and life sciences sectors. His current board directorships include Club Champion, eClinical Solutions, EHE, LumaBridge, and ModMed.
Mr. deLaar’s previous board and investment experience includes Advance Health (acquired by New Mountain Capital), Anesthetix (acquired by TeamHealth), Autobase (acquired by Dominion Enterprises), COMS Interactive (acquired by PointClickCare), Fermentas International (acquired by Thermo Fisher Scientific), Immco Diagnostics (acquired by Trinity Biotech), LakePharma (acquired by Curia), MDVIP (acquired by Goldman Sachs and Charlesbank Capital), My Dentist Holdings (acquired by Heartland Dental Care), OB Hospitalist Group (acquired by Ares Management), Surgical Affiliates Management Group (SAMGI – acquired by Varsity Healthcare Partners), and Wellcentive (acquired by Philips).
Prior to Summit, Mr. deLaar worked for DB Alex Brown, Banc of America Securities and Public Financial Management, and served in the United States Army. He holds a BS from the United States Military Academy and an MBA from the MIT Sloan School of Management.
Mark Shankar, MD
Summit Partners | Board Member
Mark Shankar is the vice president of the healthcare & life sciences team at Summit Partners. Dr. Shankar focuses primarily on the healthcare & life sciences sector. His investment and board experience includes LumaBridge.
Prior to Summit, Mark worked on the Healthcare Investment Banking Team at Goldman Sachs. In addition, he served as a clinical assistant professor of emergency medicine at the Columbia University Vagelos College of Physicians & Surgeons and was the Chief Emergency Medicine Resident at New York Presbyterian Hospital.
Mark holds a BA from the University of California, Berkeley, an MD from the George Washington University School of Medicine, and an MBA from Harvard Business School.
Summit Partners | Board Member
Mark Shankar is the vice president of the healthcare & life sciences team at Summit Partners. Dr. Shankar focuses primarily on the healthcare & life sciences sector. His investment and board experience includes LumaBridge.
Prior to Summit, Mark worked on the Healthcare Investment Banking Team at Goldman Sachs. In addition, he served as a clinical assistant professor of emergency medicine at the Columbia University Vagelos College of Physicians & Surgeons and was the Chief Emergency Medicine Resident at New York Presbyterian Hospital.
Mark holds a BA from the University of California, Berkeley, an MD from the George Washington University School of Medicine, and an MBA from Harvard Business School.
Steven White
Chief Business Officer | Board Member
Steven White is the CBO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work. He believes in the mission—and the people—of LumaBridge.
During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.
Chief Business Officer | Board Member
Steven White is the CBO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work. He believes in the mission—and the people—of LumaBridge.
During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.
Todd M. Lehman, MS
Chief Executive Officer | Board Member
Todd Lehman joined LumaBridge in 2023 with over 20 years of experience in the client services space across both commercial and clinical operations. Prior to joining LumaBridge, Mr. Lehman held various leadership roles in operations and portfolio management with a focus on the biotech customer during his tenure at PPD, part of Thermo Fisher Scientific. He got his start in the industry with Rx Development Resources, a start-up niche CRO that transformed into a small biotech, Sirion Therapeutics, and successfully in-licensed 5 ophthalmology assets while receiving 2 marketing approvals.
Mr. Lehman has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor degree in chemical engineering and a master in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Mr. Lehman spent about 10 years in retail and b2b commodity sales.
Chief Executive Officer | Board Member
Todd Lehman joined LumaBridge in 2023 with over 20 years of experience in the client services space across both commercial and clinical operations. Prior to joining LumaBridge, Mr. Lehman held various leadership roles in operations and portfolio management with a focus on the biotech customer during his tenure at PPD, part of Thermo Fisher Scientific. He got his start in the industry with Rx Development Resources, a start-up niche CRO that transformed into a small biotech, Sirion Therapeutics, and successfully in-licensed 5 ophthalmology assets while receiving 2 marketing approvals.
Mr. Lehman has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor degree in chemical engineering and a master in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Mr. Lehman spent about 10 years in retail and b2b commodity sales.
Jack Hoppin, PhD
Board Member
Jack Hoppin is the CEO and co-founder of Ratio Therapeutics, a pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms.
Dr. Hoppin has over 20 years of research and business development experience in the field of nuclear medicine. His industry experience began at Bioscan, Inc. where he served as the vice president of imaging systems and managed the development, launch, and commercialization of the NanoSPECT/CT system. In 2008, he co-founded Invicro with the mission of providing innovative medical imaging data analytics and software to the pharmaceutical industry. Invicro was sold to Konica Minolta in 2017 and Dr. Hoppin served as president of their precision medicine business unit from 2019 through 2021. Dr. Hoppin began working with Noria Therapeutics in 2018, joining their board of directors in 2019 and supporting the subsequent funding of subsidiary PSMA Therapeutics. Dr. Hoppin served as lead director as the Noria and PSMA Therapeutics organizations were sold to Bayer Healthcare in June of 2021. In conjunction with said transaction, he and fellow Noria teammates formed Ratio Therapeutics. Dr. Hoppin serves on multiple boards in the life sciences space and is a founding member of Emit Imaging, Cerveau Technologies, and Sentonix.
Board Member
Jack Hoppin is the CEO and co-founder of Ratio Therapeutics, a pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms.
Dr. Hoppin has over 20 years of research and business development experience in the field of nuclear medicine. His industry experience began at Bioscan, Inc. where he served as the vice president of imaging systems and managed the development, launch, and commercialization of the NanoSPECT/CT system. In 2008, he co-founded Invicro with the mission of providing innovative medical imaging data analytics and software to the pharmaceutical industry. Invicro was sold to Konica Minolta in 2017 and Dr. Hoppin served as president of their precision medicine business unit from 2019 through 2021. Dr. Hoppin began working with Noria Therapeutics in 2018, joining their board of directors in 2019 and supporting the subsequent funding of subsidiary PSMA Therapeutics. Dr. Hoppin served as lead director as the Noria and PSMA Therapeutics organizations were sold to Bayer Healthcare in June of 2021. In conjunction with said transaction, he and fellow Noria teammates formed Ratio Therapeutics. Dr. Hoppin serves on multiple boards in the life sciences space and is a founding member of Emit Imaging, Cerveau Technologies, and Sentonix.
David Dworaczyk, PhD
Board Member
David Dworaczyk is a highly experienced senior executive who has done extensive work with healthcare, pharma, biotech, informatics, diagnostic, and CRO companies as well as life and health science–focused venture and private equity investment groups assessing and evaluating investment opportunities from an operational, strategic, and business potential perspective. He was most recently the CEO and a board member at Bryn Pharma, an early-stage pharma company focusing on anaphylaxis, until retiring at the end of 2023. He also recently concluded a long board member tenure at Catalyst Clinical Research, an oncology-focused CRO.
Dr. Dworaczyk has over 44 years of experience as a board member, CEO, and senior executive with proven ability to build, develop, and grow international businesses. He is a highly strategic and results–focused visionary leader for building and developing early stage, turn-around, and established companies, with repeated success in leading early stage and established companies to the next level of growth and expansion. He has extensive and diverse experience that provides valuable perspectives and insights to boards and corporate management across the company in setting vision, focus, goals, and strategies that produce the best possible results, balancing drive and passion for growth with fiscal responsibility while generating the highest possible ROI.
Board Member
David Dworaczyk is a highly experienced senior executive who has done extensive work with healthcare, pharma, biotech, informatics, diagnostic, and CRO companies as well as life and health science–focused venture and private equity investment groups assessing and evaluating investment opportunities from an operational, strategic, and business potential perspective. He was most recently the CEO and a board member at Bryn Pharma, an early-stage pharma company focusing on anaphylaxis, until retiring at the end of 2023. He also recently concluded a long board member tenure at Catalyst Clinical Research, an oncology-focused CRO.
Dr. Dworaczyk has over 44 years of experience as a board member, CEO, and senior executive with proven ability to build, develop, and grow international businesses. He is a highly strategic and results–focused visionary leader for building and developing early stage, turn-around, and established companies, with repeated success in leading early stage and established companies to the next level of growth and expansion. He has extensive and diverse experience that provides valuable perspectives and insights to boards and corporate management across the company in setting vision, focus, goals, and strategies that produce the best possible results, balancing drive and passion for growth with fiscal responsibility while generating the highest possible ROI.
Dave Boyle
Board Member
Dave is a longtime veteran of the biopharma industry and has held senior management positions in the Ares Serono Group, Salix Pharmaceuticals, XOMA, AVI BioPharma, and most recently, LakePharma. At LakePharma, Dave assisted with the successful sale of the business to Curia Global.
Board Member
Dave is a longtime veteran of the biopharma industry and has held senior management positions in the Ares Serono Group, Salix Pharmaceuticals, XOMA, AVI BioPharma, and most recently, LakePharma. At LakePharma, Dave assisted with the successful sale of the business to Curia Global.